Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00806650 · ClinicalTrials.gov registry record
Anti-IMP3 Autoantibody and MicroRNA Signature Blood Tests in Finding Metastasis in Patients With Localized or Metastatic Kidney Cancer
A clinical trial, sponsored by City of Hope Medical Center.
- Completed
- Registry status
- 155
- Enrollment target
NCT00806650: Completed study, sponsored by City of Hope Medical Center.
NCT00806650 is a clinical trial that has completed, run by City of Hope Medical Center. The registered enrollment target is 155 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00806650 has completed, sponsored by City of Hope Medical Center.
- COMPLETED
- Registry status
- 155 participants
- Enrollment target
Study Summary
This research trial studies the development of a blood test for detecting anti-insulin-like growth factor II mRNA binding protein 3 (anti-IMP3) antibody and micro ribonucleic acid (microRNA) in patients with renal cell carcinoma (RCC) that has spread to other parts of the body (metastatic) or is limited to the tissue or organ where it began (localized). Anti-IMP3 is a tumor marker that can be detected in many human cancers, including RCC and is likely to be present in the serum (blood) of patients with metastatic or localized RCC. Alterations in microRNA expression has also shown to play a critical role in cancer progression and may be a promising biomarker for patients with RCC. Developing a blood test for anti-IMP3 antibody and microRNA in serum and tissue samples of patients in the laboratory may help doctors find and diagnose RCC earlier, find out how far the disease has spread, and plan effective treatment for RCC.
Primary Outcome
For the IMP3 autoantibody study, the results of IHC studies of IMP3 on the tissue sections will be used as golden standard to evaluate the sensitivity and specificity of the assay. Statistical significance will be set at P \< 0.05 (confidence level of 95%).
Interventions
- GENETIC gene expression analysis
- GENETIC protein expression analysis
- OTHER immunohistochemistry staining method
- OTHER immunoenzyme technique
- DIAGNOSTIC_TEST diagnostic laboratory biomarker analysis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 155 participants |
| Start Date | 2008-07 |
| Est. Completion | 2017-11-15 |
What the finished NCT00806650 record still lists
NCT00806650 is an observational study that tracks outcomes without assigning an intervention. The registered 155 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 5 interventions - of which gene expression analysis is the first listed.
NCT00806650 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00806650 about?
NCT00806650 is a clinical study titled "Anti-IMP3 Autoantibody and MicroRNA Signature Blood Tests in Finding Metastasis in Patients With Localized or Metastatic Kidney Cancer". This research trial studies the development of a blood test for detecting anti-insulin-like growth factor II mRNA binding protein 3 (anti-IMP3) antibody and micro ribonucleic acid (microRNA) in patients with renal cell carcinoma (RCC) that has spread to other parts of the body (metastatic) or is lim...
What is the current status of trial NCT00806650?
This trial is currently completed. The enrollment target is 155 participants. The study started on 2008-07. Estimated completion is 2017-11-15.
What interventions are being tested in trial NCT00806650?
The interventions under investigation include: gene expression analysis (GENETIC), protein expression analysis (GENETIC), immunohistochemistry staining method (OTHER), immunoenzyme technique (OTHER), diagnostic laboratory biomarker analysis (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT00806650?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03223610 · 155 participants · Phase 1
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
- NCT05072483 · 155 participants
Natural History Study of CADASIL
- NCT05086497 · 155 participants · NA
WBSI Guided Personalized Delivery of TTFields
- NCT05412069 · 155 participants · NA
Trial to Evaluate Fecobionics in Fecal Incontinence (FI) (NORMAL and ABNORMAL-FI)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia